Study Explores Creatine's Role in Enhancing Cancer-Fighting Immune Cells
A new study from researchers at the University of California, Los Angeles, published in iScience, investigates the potential benefits of creatine, a supplement widely recognized for its role in muscle energy production, in the context of cancer treatment. The research builds on earlier findings that indicated creatine could enhance the effectiveness of killer T cells, which are essential components of the immune system's defense against cancer. The latest study reveals that creatine may also serve as an important energy source for dendritic cells, which play a supportive role in guiding T cells during immune responses.
Immunologist Lili Yang, a key researcher in the study, emphasizes that creatine's benefits extend beyond T cells, energizing the entire immune infrastructure that aids in cancer defense. This discovery could significantly enhance the effectiveness of immunotherapies, which currently only succeed in approximately 20 to 40 percent of patients. By boosting the energy levels of dendritic cells, creatine supplementation may help improve the overall immune response to tumors.
The researchers conducted experiments on cancer tumors in mice, focusing on the activity of nutrient-related genes in dendritic cells located within these tumors. They found that the creatine transporter, responsible for importing creatine into cells, was significantly more active in dendritic cells from tumors compared to those from healthy tissues. When dendritic cells were cultured without this transporter, they exhibited reduced viability and effectiveness in activating T cells, which in turn weakened the immune response.
To further validate the role of creatine, the team increased creatine levels in mouse models of melanoma. This intervention resulted in a notable slowdown in tumor growth and an increase in both the number and activity of dendritic cells. The researchers concluded that creatine metabolism plays a previously unrecognized role in regulating dendritic cell function, suggesting that creatine supplementation could enhance dendritic cell-based immunotherapies.
Despite these promising findings, the researchers caution that the evidence is currently limited to mouse models and laboratory-grown human cells. They stress the importance of consulting with healthcare professionals before cancer patients consider creatine supplementation. While creatine is generally regarded as safe at recommended doses, individual health profiles can vary significantly.
Looking ahead, the research team plans to conduct clinical trials to explore the effects of creatine supplementation in human patients undergoing immunotherapy for cancer. If these trials confirm the initial findings, creatine could represent a cost-effective and accessible strategy to improve the success rates of cancer immunotherapies. The researchers envision creatine being used both as a supplement to enhance immune responses in patients receiving treatment and as a method to improve the quality of dendritic cell-based vaccines prior to administration.




